FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206049324> ?p ?o ?g. }

• W3206049324 endingPage "40" @default.
• W3206049324 startingPage "30" @default.
• W3206049324 abstract "Oral leukoplakia is common and may, in some cases, progress to carcinoma. Proliferative leukoplakia is a progressive, often multifocal subtype with a high rate of malignant transformation compared with the more common localized leukoplakia. We hypothesized that the immune microenvironment and gene expression patterns would be distinct for proliferative leukoplakia compared with localized leukoplakia. We summarize key clinicopathologic features among proliferative leukoplakia and localized leukoplakia and compare cancer-free survival (CFS) between subgroups. We analyze immunologic gene expression profiling in proliferative leukoplakia and localized leukoplakia tissue samples (NanoString PanCancer Immune Oncology Profiling). We integrate immune cell activation and spatial distribution patterns in tissue samples using multiplexed immunofluorescence and digital image capture to further define proliferative leukoplakia and localized leukoplakia. Among N = 58 patients (proliferative leukoplakia, n = 29; localized leukoplakia, n = 29), only the clinical diagnosis of proliferative leukoplakia was associated with significantly decreased CFS (HR, 11.25; P < 0.01; 5-year CFS 46.8% and 83.6% among patients with proliferative leukoplakia and localized leukoplakia, respectively). CD8+ T cells and T regulatory (Treg) were more abundant among proliferative leukoplakia samples (P < 0.01) regardless of degree of epithelial dysplasia, and often colocalized to the dysplasia-stromal interface. Gene set analysis identified granzyme M as the most differentially expressed gene favoring the proliferative leukoplakia subgroup (log2 fold change, 1.93; Padj < 0.001). Programmed death ligand 1 (PD-L1) was comparatively overexpressed among proliferative leukoplakia samples, with higher (>5) PD-L1 scores predicting worse CFS (Padj < 0.01). Proliferative leukoplakia predicts a high rate of malignant transformation within 5 years of diagnosis. A prominent CD8+ T-cell and Treg signature along with relative PD-L1 overexpression compared with localized leukoplakia provides strong rationale for PD-1/PD-L1 axis blockade using preventative immunotherapy.This is the first in-depth profiling effort to immunologically characterize high-risk proliferative leukoplakia as compared with the more common localized leukoplakia. We observed a notable cytotoxic T-cell and Treg signature with relative overexpression of PD-L1 in high-risk proliferative leukoplakia providing a strong preclinical rationale for investigating PD-1/PD-L1 axis blockade in this disease as preventative immunotherapy." @default.
• W3206049324 created "2021-10-25" @default.
• W3206049324 creator A5000093060 @default.
• W3206049324 creator A5022139249 @default.
• W3206049324 creator A5028264464 @default.
• W3206049324 creator A5036875036 @default.
• W3206049324 creator A5038244791 @default.
• W3206049324 creator A5055183931 @default.
• W3206049324 creator A5058382205 @default.
• W3206049324 creator A5058975989 @default.
• W3206049324 creator A5061963925 @default.
• W3206049324 creator A5066002385 @default.
• W3206049324 creator A5075280020 @default.
• W3206049324 creator A5080875822 @default.
• W3206049324 creator A5084967339 @default.
• W3206049324 creator A5089629546 @default.
• W3206049324 date "2021-10-13" @default.
• W3206049324 modified "2023-10-03" @default.
• W3206049324 title "Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia" @default.
• W3206049324 cites W1630865570 @default.
• W3206049324 cites W1661441964 @default.
• W3206049324 cites W1999349058 @default.
• W3206049324 cites W2001965307 @default.
• W3206049324 cites W2008671776 @default.
• W3206049324 cites W2087776529 @default.
• W3206049324 cites W2101642846 @default.
• W3206049324 cites W2110088596 @default.
• W3206049324 cites W2115140303 @default.
• W3206049324 cites W2115251794 @default.
• W3206049324 cites W2130351739 @default.
• W3206049324 cites W2201306698 @default.
• W3206049324 cites W2474496432 @default.
• W3206049324 cites W2494170285 @default.
• W3206049324 cites W2544151992 @default.
• W3206049324 cites W2596871774 @default.
• W3206049324 cites W2753945613 @default.
• W3206049324 cites W2758586749 @default.
• W3206049324 cites W2761773221 @default.
• W3206049324 cites W2782676239 @default.
• W3206049324 cites W2782941927 @default.
• W3206049324 cites W2788797147 @default.
• W3206049324 cites W2799990159 @default.
• W3206049324 cites W2809092757 @default.
• W3206049324 cites W2888854634 @default.
• W3206049324 cites W2891658508 @default.
• W3206049324 cites W2899145148 @default.
• W3206049324 cites W2936439530 @default.
• W3206049324 cites W2941582519 @default.
• W3206049324 cites W2959474656 @default.
• W3206049324 cites W2980642079 @default.
• W3206049324 cites W2986633517 @default.
• W3206049324 cites W2996689501 @default.
• W3206049324 cites W3004065850 @default.
• W3206049324 cites W3004087021 @default.
• W3206049324 cites W3006281883 @default.
• W3206049324 cites W3029297598 @default.
• W3206049324 cites W3029332117 @default.
• W3206049324 cites W3119680478 @default.
• W3206049324 cites W3129357027 @default.
• W3206049324 cites W578277296 @default.
• W3206049324 doi "https://doi.org/10.1158/2767-9764.crc-21-0060" @default.
• W3206049324 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36860910" @default.
• W3206049324 hasPublicationYear "2021" @default.
• W3206049324 type Work @default.
• W3206049324 sameAs 3206049324 @default.
• W3206049324 citedByCount "8" @default.
• W3206049324 countsByYear W32060493242022 @default.
• W3206049324 countsByYear W32060493242023 @default.
• W3206049324 crossrefType "journal-article" @default.
• W3206049324 hasAuthorship W3206049324A5000093060 @default.
• W3206049324 hasAuthorship W3206049324A5022139249 @default.
• W3206049324 hasAuthorship W3206049324A5028264464 @default.
• W3206049324 hasAuthorship W3206049324A5036875036 @default.
• W3206049324 hasAuthorship W3206049324A5038244791 @default.
• W3206049324 hasAuthorship W3206049324A5055183931 @default.
• W3206049324 hasAuthorship W3206049324A5058382205 @default.
• W3206049324 hasAuthorship W3206049324A5058975989 @default.
• W3206049324 hasAuthorship W3206049324A5061963925 @default.
• W3206049324 hasAuthorship W3206049324A5066002385 @default.
• W3206049324 hasAuthorship W3206049324A5075280020 @default.
• W3206049324 hasAuthorship W3206049324A5080875822 @default.
• W3206049324 hasAuthorship W3206049324A5084967339 @default.
• W3206049324 hasAuthorship W3206049324A5089629546 @default.
• W3206049324 hasBestOaLocation W32060493241 @default.
• W3206049324 hasConcept C121608353 @default.
• W3206049324 hasConcept C126322002 @default.
• W3206049324 hasConcept C142724271 @default.
• W3206049324 hasConcept C2775894508 @default.
• W3206049324 hasConcept C2777550702 @default.
• W3206049324 hasConcept C2781340805 @default.
• W3206049324 hasConcept C502942594 @default.
• W3206049324 hasConcept C71924100 @default.
• W3206049324 hasConceptScore W3206049324C121608353 @default.
• W3206049324 hasConceptScore W3206049324C126322002 @default.
• W3206049324 hasConceptScore W3206049324C142724271 @default.
• W3206049324 hasConceptScore W3206049324C2775894508 @default.
• W3206049324 hasConceptScore W3206049324C2777550702 @default.
• W3206049324 hasConceptScore W3206049324C2781340805 @default.

• next